title: [Ki-67 and cyclin A--prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine].
authors.affiliation: Gynonkologiska kliniken, Universitetssjukhuset, Orebro. ahlins.post@telia.com
authors.forename: Cecilia
authors.initials: C
authors.lastname: Ahlin
authors.forename: Mårten
authors.initials: M
authors.lastname: Fernö
authors.forename: Rose-Marie
authors.initials: RM
authors.lastname: Amini
authors.forename: Egle
authors.initials: E
authors.lastname: Tolockiene
authors.forename: Carl
authors.initials: C
authors.lastname: Blomqvist
authors.forename: Jonas
authors.initials: J
authors.lastname: Bergh
authors.forename: Marie-Louise
authors.initials: ML
authors.lastname: Fjällskog
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D049109:Cell Proliferation; D017024:Chemotherapy, Adjuvant; D019925:Cyclin A / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D008940:Mitotic Index; D011379:Prognosis; D015203:Reproducibility of Results
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019925:Cyclin A; D019394:Ki-67 Antigen